The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:
1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify?
2. What percentage of patients achieve a clinical response?
Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

开始日期2025-01-01

申办/合作机构

Montefiore Medical Center

[+1]

NCT06411002

/ Recruiting临床2期

A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines

This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL).
Approximately 40 subjects (18 years of age and above) with moderate to severe GL and FHL (all assessed at maximum contraction) will be screened for eligibility with the goal of enrolling and treating 30 subjects to receive DAXI for injection after providing informed consent.
The primary objective of this study is to determine the efficacy and safety of the combined treatment of two upper facial regions with DAXI for injection.

开始日期2024-04-08

申办/合作机构

Revance Therapeutics, Inc.

NCT06225492

/ Recruiting临床4期IIT

Use of DaxibotulinimtoxinA Injection for Platysma Bands of the Neck

This study seeks to evaluate the effectiveness and duration of action of DaxibotulinumtoxinA for neck rejuvenation through treatment of platysmal bands. This study will consist of one treatment visit with subjects being randomized to receiving 15 or 20 units of DaxibotulinumtoxinA per platysmal band. Subjects will return for 5 follow-up visits at 8, 12, 16, 20, and 24 weeks for evaluation.

开始日期2024-01-01

申办/合作机构

Main Line Center for Laser Surgery

100 项与 Daxibotulinumtoixn A-LANM 相关的临床结果

登录后查看更多信息

100 项与 Daxibotulinumtoixn A-LANM 相关的转化医学

登录后查看更多信息

100 项与 Daxibotulinumtoixn A-LANM 相关的专利（医药）

登录后查看更多信息

项与 Daxibotulinumtoixn A-LANM 相关的文献（医药）

2025-01-01·JOURNAL OF VOICE

DaxibotulinumtoxinA Treatment for Laryngeal Respiratory Dystonia

Article

作者: Rosen, Clark A ; Marshall, Camryn

BACKGROUND:

Laryngeal respiratory dystonia (LRD) is diagnosed based on clinical presentation, patient history, and physical examination. Key indicators include dyspnea, desynchronized breathing patterns, and laryngoscopic findings that reveal vocal fold adduction during inspiration. Treatment for LRD remains controversial and often yields limited effectiveness. While botulinum toxin type A (BtxA) is commonly injected into the thyroarytenoid-lateral cricothyroid (TA-LCA) muscle complex, there are cases where injections into the interarytenoid (IA) muscle have also proven beneficial. DaxibotulinumtoxinA (DAXI) is an emerging therapy that has shown promising effectiveness and safety across various conditions, including cervical dystonia. In this report, we present the first documented use of DAXI specifically for LRD, highlighting the significant benefits experienced by the patient compared to previous treatments with BtxA.

CASE:

A 77-year-old man presented with a 1-year history of significant shortness of breath. Laryngeal endoscopy demonstrated inappropriate adduction of the patient's vocal folds during respiration, suggestive of LRD. The patient received their first Botox (BtxA) injection in May 2018 and has since undergone a total of 40 injections. The patient had a variable response to BtxA injection into his TA-LCA muscle complex, experiencing general improvement in breathing but frequent negative impact on voice and swallowing function. In November of 2021, electromyography-guided BtxA injection into the patient's IA muscle was performed with significant improvement in results. The patient described near-complete resolution of his LRD breathing symptoms with minimal voice changes and a duration of benefit of ~50 days. In November of 2023, DAXI injection into the patient's IA muscle was performed. The patient self-reported a complete resolution of his symptoms for a total duration of benefit of 91 days. Subsequent injections with DAXI in February and May of 2024 had near identical responses.

CONCLUSION:

DAXI appears to provide ~80% better duration than the patient's average BtxA injection and a 57% improvement than his best BtxA injection. DAXI is a safe and realistic alternative to BtxA injection in patients with LRD.

2024-12-01·Journal of Plastic Reconstructive and Aesthetic Surgery

DaxibotulinumtoxinA for injection to treat moderate or severe glabellar lines: A randomized, multicenter, Phase III, double-blind, placebo-controlled trial in China

Article

作者: Ge, Lei ; Wang, Hui ; Sun, Jiaming ; Li, Li ; Li, Qingfeng ; Guo, Qing ; Wang, Xingli ; Wang, Baoxi ; Liu, Quanzhong ; Fan, Xiaojing ; Su, Juan ; Zhao, Hongyi ; Xie, Yun

BACKGROUND:

DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin type A formulation, is FDA-approved for glabellar lines treatment. Its clinical efficacy has been demonstrated in two Phase III trials (SAKURA 1 and SAKURA 2).

OBJECTIVE:

To evaluate DAXI efficacy and safety in Chinese adults with moderate/severe glabellar lines.

METHODS:

In this Phase III, randomized (2:1), double-blind trial, Chinese adults with moderate/severe glabellar lines received 40 U DAXI or placebo into the corrugator muscles bilaterally and the procerus. Glabellar line severity was evaluated by investigators (Investigator Global Assessment-Frown Wrinkle Severity [IGA-FWS] scale) and participants (Patient Frown Wrinkle Severity [PFWS] scale) for ≥24 to 36 weeks. The primary endpoint was the proportion of 2-point composite responders achieving ≥2-point reduction in IGA-FWS and PFWS scores at week 4 post-treatment.

RESULTS:

Overall, 307 participants received treatment (DAXI, 205; placebo, 102). A significantly greater proportion of participants in the DAXI arm vs the placebo arm achieved a 2-point composite response at week 4: 125 (61.0%) vs 1 (1.0%); difference, 60.0% [95% CI 49.40-66.46]; 2-sided p < 0.0001). At week 4, 94.1% of the DAXI-treated participants achieved an IGA-FWS score 0/1 (none/mild) and 86.3% achieved PFWS 0/1; median time to loss of none/mild on IGA-FWS and PFWS was 23.9 weeks. The benefits of DAXI over placebo through week 24 occurred regardless of the baseline IGA-FWS score, prior botulinum toxin type A (BoNTA) exposure, sex or age. DAXI was well tolerated with no new safety signals.

CONCLUSION:

DAXI provided durable efficacy and acceptable safety for treating moderate/severe glabellar lines in Chinese participants.

2024-09-01·DERMATOLOGIC SURGERY

Clinical Benefits of DaxibotulinumtoxinA for Injection: Beyond Glabellar Line Effacement?

Review

作者: Shamban, Ava ; Green, Jeremy B. ; Gross, Todd M. ; Mariwalla, Kavita ; Brown, Jessica ; Gallagher, Conor J.

BACKGROUND:

Botulinum toxin type A (BoNTA) is standard of care for glabellar lines ameliorization. DaxibotulinumtoxinA for Injection (DAXI) is a new BoNTA with a unique formulation representing the latest advancement in BoNTA technology. There is an unmet need for patients to understand the full potential of BoNTA treatment and new technologies.

OBJECTIVE:

To update clinical data supporting the use of DAXI for glabellar lines within the context of clinical experience.

MATERIALS AND METHODS:

A narrative review of the literature and summary of clinical experience with DAXI.

RESULTS:

The DAXI clinical trial program reflects clinical experience post-FDA approval, with DAXI demonstrating rapid onset, high patient response rates, and extended treatment duration versus conventional BoNTAs. Clinical observations suggest that DAXI has limited diffusion from the injection site, enabling more localized control of muscle activity and greater improvements in wrinkle severity. DAXI enables practitioners to exert greater finesse in their injections and in predicting changes to eyebrow shape and position and achieve improvement in skin quality.

CONCLUSION:

Advances in BoNTA technology can provide patients with greater options for treatment outcomes. The potential for enhanced localized effects with DAXI may contribute to more precise and targeted effects on muscle activity and additional aesthetic benefits to patients.

136

项与 Daxibotulinumtoixn A-LANM 相关的新闻（医药）

2025-02-05

·Endpoints

Revance and Crown are almost ready to close their deal after earlier bidding war

The fight over who gets control of Revance Therapeutics and its Botox competitor, Daxxify, is coming to a close. On Wednesday, Revance said it’s moving forward with its sale to Crown Laboratories. The two companies had been in talks for months when, in January, Revance’s commercial partner Teoxane submitted a competing bid . Crown had initially offered $6.66 per share in August to acquire Revance. Shortly after, Teoxane initiated a contract dispute with Revance that delayed the deal and was a factor in Crown’s decision to slash its offer to $3.10 a share. Teoxane, which develops dermal fillers, then proposed to buy Revance for $3.60 per share. Teoxane argued that its offer was a “superior, attractive and actionable alternative” to Crown’s deal. But Crown CEO Jeff Bedard said in a letter to Revance’s board of directors that Teoxane’s actions “have been clearly designed to disrupt a transaction involving Revance and Crown, to the significant detriment of Revance and its stockholders.” Revance said it would talk to Teoxane about its offer. But when Crown raised its bid to $3.65 per share late last month, Revance said the Crown proposal was “the only fully financed offer currently available.” The companies expect to close the deal on Thursday, they announced in a joint press release. Daxxify has been approved since 2022 as a treatment for moderate-to-severe glabellar lines, otherwise known as frown lines. It’s also approved to treat cervical dystonia, a condition in which the neck muscles contract uncontrollably. However, Crown has expressed a particular interest in the aesthetics side of Revance’s business.

上市批准并购

2025-02-05

·PRNewswire

Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer

JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Feb. 5, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance at a purchase price of $3.65 per Share, net to the stockholder in cash without interest and less any required tax withholding (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 and was not extended (such date and time, the "Expiration Time"). Continue Reading Revance Therapeutics, Inc. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, has advised Crown that, as of the Expiration Time, 86,197,893 Shares were validly tendered and not validly withdrawn in the Offer, representing 82.0% of the issued and outstanding Shares as of the Expiration Time. Accordingly, all conditions to the Offer have been satisfied. Crown and its affiliate, Reba Merger Sub, Inc. ("Merger Sub"), will promptly accept for payment, and will promptly pay for, all Shares validly tendered and not validly withdrawn in the Offer. The parties expect to consummate the acquisition on February 6, 2025, in accordance with, and subject to the terms of, the definitive agreement for the proposed acquisition. Advisors Centerview Partners LLC is serving as exclusive financial advisor for Revance; Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor for Revance. Leerink Partners and PJT Partners are serving as financial advisors to Crown; Kirkland & Ellis LLP and Lowenstein Sandler LLP are serving as legal advisors to Crown. About Crown Crown, a privately held, fully integrated global skincare company, is committed to developing and providing a diverse portfolio of aesthetic, premium and therapeutic skincare products that improve the quality of life for its consumers throughout their skincare journey. An innovative company focused on skin science for life, Crown's unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it has become a leader in Dermatology and Aesthetics. Crown has been listed on the Inc. 5000 Fastest Growing Privately Held Companies List for 11 years and has expanded its distribution to over 50 countries. For more information, visit . The "Crown" logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company, Inc., respectively. About Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA. Revance has partnered with Teoxane SA to supply HA fillers for U.S. distribution. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China. Revance's global headquarters and experience center are located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn. "Revance," the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA. Additional Information and Where to Find It This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Crown and Merger Sub, filed with the U.S. Securities and Exchange Commission (the "SEC"). The solicitation and offer to buy outstanding Shares of Revance was only made pursuant to the tender offer materials that Crown and Merger Sub filed with the SEC. The tender offer materials are available for free on the SEC's website at . Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." The use of words such as "anticipates," "hopes," "may," "should," "intends," "projects," "estimates," "expects," "plans" and "believes," among others, generally identify forward-looking statements. All statements, other than statements of historical fact, are forward-looking statements. These forward-looking statements include, among others, statements relating to Revance's and Crown's future financial performance, business prospects and strategy, expectations with respect to the anticipated merger, including the timing thereof and Revance's and Crown's ability to successfully complete such transactions and realize the anticipated benefits. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others, the risks and uncertainties inherent in the anticipated merger, including, among other things, the ability to satisfy the conditions to the closing of the anticipated merger, the expected timing of the anticipated merger, the possibility that the anticipated merger will not be completed, difficulties or unanticipated expenses in connection with integrating the parties' operations, products and employees and the possibility that anticipated synergies and other anticipated benefits of the transaction will not be realized in the amounts expected, within the expected timeframe or at all, the effect of the anticipated merger on Revance's and Crown's business relationships (including, without limitations, partners and customers), the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, the expected tax treatment of the transaction, and the impact of the transaction on the businesses of Revance and Crown, and other circumstances beyond Revance's and Crown's control. You should not place undue reliance on these forward-looking statements. Certain of these and other risks and uncertainties are discussed in Revance's and Crown's filings with the SEC, including the Schedule TO (including the offer to purchase, a related letter of transmittal and related documents) Crown and its acquisition subsidiary have filed with the SEC, and the Solicitation/Recommendation Statement on Schedule 14D-9 Revance has filed with the SEC, and Revance's most recent Form 10-K and Form 10-Q filings with the SEC. Except as required by law, neither Revance nor Crown undertakes any duty to update forward-looking statements to reflect events after the date of this press release. Contacts Media: Alecia Pulman ICR [email protected] Investors: Laurence Watts NewStreet [email protected] SOURCE Crown Laboratories, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购

2025-01-31

·PRNewswire

Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline

Crown offer of $3.65 per share is the only offer available to Revance stockholders Crown offer unanimously approved by the Revance Board of Directors Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender Tender offer expires at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 31, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today reminded Revance stockholders of the recommendation to tender their shares in support of Crown's cash tender offer (the "tender offer") to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance, at a price of $3.65 per Share in cash, without interest and less any applicable tax withholding, before the expiry of the tender offer at one minute past 11:59 p.m., Eastern Time, on February 4, 2025. Continue Reading Revance Therapeutics, Inc. Mark J. Foley, Chief Executive Officer of Revance said: "The Crown tender offer of $3.65 per share has been unanimously approved by the Revance Board of Directors. After a robust process, our Board concluded that Crown's offer represents the best outcome for our stockholders. Now that Teoxane has withdrawn their previous proposal and has indicated that they will tender their shares in support of the Crown transaction, the Crown offer is the only acquisition offer available to shareholders. To complete the transaction, stockholders must tender their shares before the expiration of the tender offer at one minute past 11:59 p.m., Eastern Time, on February 4th." Crown's offer is the ONLY OFFER available to Revance stockholders The Crown tender offer of $3.65 per Share in cash, without interest and less any applicable tax withholding, which has been unanimously recommended by Revance's Board of Directors, is the only offer available to Revance stockholders. Teoxane INTENDS TO TENDER its shares in Crown's tender offer On January 30th, Teoxane SA announced that it has withdrawn its non-binding proposal to acquire Revance and intends to tender all of its Shares, representing a 6.2% stake, in the tender offer. Revance stockholders must tender by FEBRUARY 4 DEADLINE for transaction to close Crown's tender offer will expire at one minute past 11:59 p.m. Eastern Time, on February 4, 2025. The outside termination date under the Amended and Restated Merger Agreement, dated December 7, 2024 (the "A&R Merger Agreement") remains February 7, 2025. Crown reiterates that it does not intend to extend the outside termination date of the A&R Merger Agreement. Subject to customary closing conditions, including the tender of more than 50% of the Shares into the tender offer, the transaction is expected to close by February 6, 2025. Tender Offer Details Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Crown that, as of 4:00 p.m., Eastern Time, on January 30, 2025, approximately 10,946,712 Shares have been validly tendered and not properly withdrawn in the tender offer, representing approximately 10.4313% of the issued and outstanding Shares, as of such date and time. Holders that have previously tendered their Shares do not need to re-tender their Shares or take any other action. The tender offer continues to be subject to the remaining conditions set forth in the Offer to Purchase that Crown and its acquisition subsidiary filed with the Securities and Exchange Commission ("SEC"), as amended or supplemented from time to time. Complete terms and conditions of the tender offer can be found in the Offer to Purchase, the Letter of Transmittal, and certain other materials contained in the tender offer statement on Schedule TO originally filed with the SEC on December 12, 2024 by Crown and its acquisition subsidiary, as amended and as may be further amended from time to time, and are available at . The terms of the tender offer remain the same as set forth in the Offer to Purchase, the Letter of Transmittal, in each case, as amended. Advisors Centerview Partners LLC is serving as exclusive financial advisor for Revance; Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor for Revance. Leerink Partners and PJT Partners are serving as financial advisors to Crown; Kirkland & Ellis LLP and Lowenstein Sandler LLP are serving as legal advisors to Crown. About Crown Crown, a privately held, fully integrated global skincare company, is committed to developing and providing a diverse portfolio of aesthetic, premium and therapeutic skincare products that improve the quality of life for its consumers throughout their skincare journey. An innovative company focused on skin science for life, Crown's unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it has become a leader in Dermatology and Aesthetics. Crown has been listed on the Inc. 5000 Fastest Growing Privately Held Companies List for 11 years and has expanded its distribution to over 50 countries. For more information, visit . The "Crown" logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company, Inc., respectively. About Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA. Revance has partnered with Teoxane SA to supply HA fillers for U.S. distribution. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China. Revance's global headquarters and experience center are located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn. "Revance," the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA. Additional Information and Where to Find It In connection with its proposed acquisition of Revance, Crown caused its acquisition subsidiary to commence a tender offer to acquire all outstanding Shares of Revance. This communication is for informational purposes only and is not an offer to buy nor a solicitation of an offer to sell any securities of Revance, nor is it a substitute for the tender offer materials that Crown and its acquisition subsidiary filed with the SEC upon commencement of the tender offer. A solicitation and offer to buy all outstanding Shares of Revance is only being made pursuant to the tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that Crown and its acquisition subsidiary have filed with the SEC. In addition, Revance has filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF REVANCE ARE URGED TO READ THESE DOCUMENTS CAREFULLY (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF REVANCE SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. Investors may obtain a free copy of these materials (including the tender offer statement, Offer to Purchase and a related Letter of Transmittal, as well as the Solicitation/Recommendation Statement) and other documents filed by Crown and Revance with the SEC at the website maintained by the SEC at . Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by Revance under the "News" section of Revance's website at . The information contained in, or that can be accessed through, Revance's or Crown's website is not a part of, or incorporated by reference herein. Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." The use of words such as "anticipates," "hopes," "may," "should," "intends," "projects," "estimates," "expects," "plans" and "believes," among others, generally identify forward-looking statements. All statements, other than statements of historical fact, are forward-looking statements. These forward-looking statements include, among others, statements relating to Revance's and Crown's future financial performance, business prospects and strategy, expectations with respect to the tender offer and the anticipated merger, including the timing thereof and Revance's and Crown's ability to successfully complete such transactions and realize the anticipated benefits. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others, the risks and uncertainties inherent in the tender offer and the anticipated merger, including, among other things, regarding how many of Revance's stockholders will tender their Shares in the tender offer, the possibility that competing offers will be made, the ability to obtain requisite regulatory approvals, the ability to satisfy the conditions to the closing of the tender offer and the anticipated merger, the expected timing of the tender offer and the anticipated merger, the possibility that the anticipated merger will not be completed, difficulties or unanticipated expenses in connection with integrating the parties' operations, products and employees and the possibility that anticipated synergies and other anticipated benefits of the transaction will not be realized in the amounts expected, within the expected timeframe or at all, the effect of the tender offer and the anticipated merger on Revance's and Crown's business relationships (including, without limitations, partners and customers), the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, the expected tax treatment of the transaction, and the impact of the transaction on the businesses of Revance and Crown, and other circumstances beyond Revance's and Crown's control. You should not place undue reliance on these forward-looking statements. Certain of these and other risks and uncertainties are discussed in Revance's and Crown's filings with the SEC, including the Schedule TO (including the offer to purchase, a related letter of transmittal and related documents) Crown and its acquisition subsidiary have filed with the SEC, and the Solicitation/Recommendation Statement on Schedule 14D-9 the Company has filed with the SEC, and Revance's most recent Form 10-K and Form 10-Q filings with the SEC. Except as required by law, neither Revance nor Crown undertakes any duty to update forward-looking statements to reflect events after the date of this press release. Contacts Media: Alecia Pulman/Brittany Fraser ICR [email protected] Investors: Laurence Watts NewStreet [email protected] SOURCE Crown Laboratories, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购

100 项与 Daxibotulinumtoixn A-LANM 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肌张力障碍	中国	上海复星医药产业发展有限公司	2024-11-22
颈肌张力障碍	美国	Revance Therapeutics, Inc.	2023-08-11
眉间纹	美国	Revance Therapeutics, Inc.	2022-09-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
斜颈	申请上市	美国	Revance Therapeutics, Inc.	2022-10-20
孤立性颈部肌张力障碍	临床3期	美国	Revance Therapeutics, Inc.	2018-09-05
孤立性颈部肌张力障碍	临床3期	奥地利	Revance Therapeutics, Inc.	2018-09-05
孤立性颈部肌张力障碍	临床3期	加拿大	Revance Therapeutics, Inc.	2018-09-05
孤立性颈部肌张力障碍	临床3期	捷克	Revance Therapeutics, Inc.	2018-09-05
孤立性颈部肌张力障碍	临床3期	法国	Revance Therapeutics, Inc.	2018-09-05
孤立性颈部肌张力障碍	临床3期	德国	Revance Therapeutics, Inc.	2018-09-05
孤立性颈部肌张力障碍	临床3期	波兰	Revance Therapeutics, Inc.	2018-09-05
孤立性颈部肌张力障碍	临床3期	西班牙	Revance Therapeutics, Inc.	2018-09-05
孤立性颈部肌张力障碍	临床3期	英国	Revance Therapeutics, Inc.	2018-09-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAN2024	N/A	颈肌张力障碍	-	DaxibotulinumtoxinA for injection (DAXI) 250U	壓顧壓築範構齋醖範積(夢餘鹽醖鹹憲鹹餘鬱夢) = 網壓網蓋膚壓齋襯選廠鏇襯選鬱餘艱窪蓋膚構 (憲夢簾醖壓鹽鹹簾獵衊 )	-	2024-04-09
AAN2024	N/A	颈肌张力障碍	-	DaxibotulinumtoxinA	壓顧選築餘襯蓋簾襯鬱(繭淵選遞壓網鏇蓋選繭) = 壓構夢鹽鏇範構衊選築製憲鏇衊夢衊齋遞糧鏇 (獵醖鹽淵鹹壓構鹹鏇觸 ) 更多	-	2024-04-09
NCT02973269 (CTgov)	临床2期	足底筋膜炎	7	daxibotulinumtoxin type A (DAXI 240 U)	鑰壓襯夢構夢膚齋蓋顧(簾選網簾鏇蓋餘壓網餘) = 網膚膚網構夢艱齋齋繭積鹹範遞壓願觸簾選觸 (憲襯鏇糧餘繭蓋製繭鑰, 網餘選鹹製壓鬱夢襯齋 ~ 願夢願衊積窪壓鑰膚願) 更多	-	2024-04-03
				Placebo (Placebo)	鑰壓襯夢構夢膚齋蓋顧(簾選網簾鏇蓋餘壓網餘) = 夢餘衊糧廠積積製鬱衊積鹹範遞壓願觸簾選觸 (憲襯鏇糧餘繭蓋製繭鑰, 積夢構願獵淵齋範餘獵 ~ 齋積醖鬱積觸製積醖糧) 更多
NCT03608397 \| EUCTR2018-000446-19-AT (ASPEN-1, Pubmed \| Neurology) 人工标引	临床3期	颈肌张力障碍	301	DAXI125U	糧窪網窪襯鑰齋鹽遞願(夢觸齋構廠鏇齋廠齋夢) = 淵夢衊窪襯憲鹹衊選鏇鏇觸艱憲鬱鏇構網選壓 (淵鏇選築壓齋選憲艱繭, 1.30) 更多	积极	2024-01-31
				DAXI250U	糧窪網窪襯鑰齋鹽遞願(夢觸齋構廠鏇齋廠齋夢) = 遞鹽觸糧鏇襯簾鑰積餘鏇觸艱憲鬱鏇構網選壓 (淵鏇選築壓齋選憲艱繭, 1.25) 更多
NCT03825315 (CTgov)	临床2期	足底筋膜炎	155	DAXI 80 U (DAXI 80 U)	鏇製選淵餘選觸糧糧鑰(鹽糧糧餘網廠襯積餘廠) = 構鏇鏇網觸鹹廠積願壓壓鑰鹹鏇網壓醖餘膚製 (鹽膚簾齋夢獵膚襯積製, 襯積構築範鹽衊製積襯 ~ 獵構醖鏇顧鑰鑰網鑰艱) 更多	-	2023-09-21
				DAXI 120 U (DAXI 120 U)	鏇製選淵餘選觸糧糧鑰(鹽糧糧餘網廠襯積餘廠) = 獵網蓋壓願鬱鏇襯鏇選壓鑰鹹鏇網壓醖餘膚製 (鹽膚簾齋夢獵膚襯積製, 衊簾築夢觸簾夢艱鏇網 ~ 廠醖壓壓製鏇積齋願餘) 更多
NCT03608397 (FDA) 人工标引	临床3期	颈肌张力障碍	301	Placebo	鑰選構餘蓋衊構壓糧膚(窪鹽艱簾積顧窪願簾鏇) = 簾醖襯憲獵憲鬱窪齋簾鏇鏇衊憲糧蓋構觸衊繭 (獵願遞艱壓願鏇壓鏇鹹 )	积极	2023-08-11
				DAXI 125 U	鑰選構餘蓋衊構壓糧膚(窪鹽艱簾積顧窪願簾鏇) = 構觸淵簾遞鹹醖願淵選鏇鏇衊憲糧蓋構觸衊繭 (獵願遞艱壓願鏇壓鏇鹹 )
GL-2 (FDA) 人工标引	N/A	眉间纹	609	DAXXIFY (STUDY GL-1)	築窪選鹹簾鏇構鬱壓廠(蓋艱襯糧簾夢蓋簾廠蓋) = 遞選膚網鬱艱觸願衊選膚蓋鬱積襯觸膚鑰範鏇 (築鑰觸憲膚繭鏇鬱膚鏇 ) 更多	积极	2023-08-11
				Placebo (STUDY GL-1)	築窪選鹹簾鏇構鬱壓廠(蓋艱襯糧簾夢蓋簾廠蓋) = 廠蓋鏇糧願築鹽蓋簾觸膚蓋鬱積襯觸膚鑰範鏇 (築鑰觸憲膚繭鏇鬱膚鏇 ) 更多
NCT03911102 (CTgov)	临床2期	外眦皱纹	63	DaxibotulinumtoxinA for injection (Cohort 1: DAXI 12 U)	網襯窪築夢醖範艱壓艱(廠簾繭壓夢簾顧鑰遞鬱) = 憲遞淵願壓繭衊憲廠觸糧蓋選壓製鏇願鑰製遞 (夢淵觸襯蓋觸遞築願積, 簾憲衊壓衊鬱鬱夢蓋淵 ~ 顧選鑰繭壓醖衊積選積) 更多	-	2023-06-27
				DaxibotulinumtoxinA for injection (Cohort 2: DAXI 24 U)	網襯窪築夢醖範艱壓艱(廠簾繭壓夢簾顧鑰遞鬱) = 鑰繭膚鹽鏇觸膚鬱衊齋糧蓋選壓製鏇願鑰製遞 (夢淵觸襯蓋觸遞築願積, 窪憲鑰構艱衊遞範膚網 ~ 糧觸繭壓積夢顧糧襯構) 更多
NCT04259086 (CTgov)	临床2期	眉间纹	48	DaxibotulinumtoxinA for injection	蓋艱遞鏇襯憲夢構鹹鹹(選齋鹹簾膚鑰範積衊艱) = 齋廠淵淵壓蓋衊製網淵願衊窪艱廠積壓鹽鹹衊 (襯簾鬱鏇遞範觸鏇鏇醖, 顧簾膚衊餘製膚鏇膚鏇 ~ 鬱鑰選糧餘窪網築鏇遞) 更多	-	2023-06-27
ASPEN-1 and ASPEN-OLS (AAN2023)	临床3期	颈肌张力障碍	-	Placebo	廠衊觸艱壓選構夢衊壓(構窪襯積齋齋鏇網製構) = 衊遞膚醖壓簾觸窪衊艱顧淵廠蓋鏇觸積積繭衊 (築鑰簾窪醖積醖網獵選 )	积极	2023-04-25
				DAXI 125U	廠衊觸艱壓選構夢衊壓(構窪襯積齋齋鏇網製構) = 觸構鹹鬱鑰淵衊醖膚製顧淵廠蓋鏇觸積積繭衊 (築鑰簾窪醖積醖網獵選 )